Skip to content

Discontinued — last reported Q4 '22

Net margin at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
4.6%+2.4pp
Biogen logo
BiogenBIIB
14.3%-0.8pp
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
21.6%+8.9pp
Insmed logo
InsmedINSM
-144.4%-45.3pp
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-1,738.4%+1,407pp
uniQure logo
uniQureQURE
-1,154.4%+89.3pp

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$910.66M+145%
Enterprise value$634.23M+244%
P/S112.5×-10.3×

Profitability

See full
Operating margin-1,315.2%-4,060pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Calculated from Solid Biosciences Inc.’s reported figures.

Based on trailing twelve months.

The official record: Solid Biosciences Inc.’s 10-K, filed March 13, 2024, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s net margin?
Solid Biosciences Inc. (SLDB) reported net margin of -1,062.3% in Q4 2022.
How has Solid Biosciences Inc.'s net margin changed year-over-year?
Solid Biosciences Inc.'s net margin decreased by 100.4% year-over-year, from -530% to -1,062.3%.
What does net margin mean?
Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.